|
|
![]() | ![]() | ![]() | ![]() |
| |||||||||
This excerpt taken from the SNY 20-F filed Apr 11, 2005. Pro forma amortization and impairment of intangibles
Pro forma charges for amortization and impairment of intangibles amounted to 3,950 million in 2004, after the elimination for pro forma purposes of 11 million of amortization relating to Arixtra® and Fraxiparine® and 94 million of amortization of Aventis intangible assets, and after recognition of a charge of 2,398 million for the amortization of the acquired intangible assets of Aventis. Overall, this represents a decrease of 5.3% relative to the 2003 pro forma figure of 4,171 million. The decrease in amortization was mainly due to the effect of exchange rates.
|
| |||||||